Antihypertensive Drugs: Action of β₁ Blockers

β1 receptors are primarily found in the heart and kidneys. In cardiac myocytes, these receptors respond to stress-induced neurotransmitters like catecholamines released by the sympathetic nervous system. In the kidneys, β1 receptors are located on juxtaglomerular cells of the afferent arteriole, where they regulate renin production and blood pressure control.

β1-blockers competitively inhibit catecholamines from binding to β1 receptors in cardiac myocytes. This prevents stress-induced overstimulation, reducing heart rate and the force of heart contraction. By decreasing the heart's workload, β1-blockers lower cardiac output and ultimately reduce hypertension and regulation of blood pressure.

When β1 receptors are overactivated in the kidneys, juxtaglomerular cells increase renin production, triggering the renin-angiotensin system and raising blood pressure. β1-blockers block this activation, reducing renin production and subsequently decreasing angiotensin II levels, which allows blood vessels to relax and lowers blood pressure.

Overactivation of β1 receptors increases renin, which elevates angiotensin II and triggers aldosterone production. Aldosterone causes the kidneys to retain sodium and water, increasing blood volume and pressure. By blocking β1 receptors, β1-blockers reduce renin and aldosterone production, decreasing sodium and water reabsorption and lowering blood volume.

Chronic stress overstimulates β1 receptors through catecholamine release, abnormally elevating heart rate and blood pressure. This sustained activation contributes to hypertension. β1-blockers counteract this by preventing catecholamines from binding to β1 receptors, reducing stress-induced cardiovascular effects and helping normalize blood pressure.

Angiotensin II is a potent vasoconstrictor produced when renin converts angiotensinogen to angiotensin I. It narrows blood vessels, increasing peripheral resistance and blood pressure. Angiotensin II also stimulates aldosterone production, promoting sodium and water retention. β1-blockers reduce angiotensin II by decreasing renin production in the kidneys.

β1-blockers lower blood pressure through cardiac and renal mechanisms. In the heart, they reduce heart rate and contractility. In the kidneys, they suppress renin production, decreasing angiotensin II and aldosterone, which reduces vasoconstriction and sodium-water retention. These dual actions make β1-blockers effective antihypertensive agents.